Collegium Pharmaceutical Inc (COLL) FinancialsCOLLCollegium Pharmaceutical Inc

Collegium Pharmaceutical Inc (COLL) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Azstarys, accounting for 106.5% of total sales, equivalent to $212.79M. Other significant revenue streams include Nucynta IR and Belbuca. Understanding this composition is critical for investors evaluating how COLL navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Collegium Pharmaceutical Inc maintains a gross margin of 55.18%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 14.60%, while the net margin is -7.53%. These profitability ratios, combined with a Return on Equity (ROE) of 17.61%, provide a clear picture of how effectively COLL converts its operational activities into shareholder value.

In the context of the broader market, COLL competes directly with industry leaders such as ACHV and RIGL. With a market capitalization of $875.11M, it holds a significant position in the sector. When comparing efficiency, COLL's gross margin of 55.18% stands against ACHV's N/A and RIGL's 89.17%. Such benchmarking helps identify whether Collegium Pharmaceutical Inc is trading at a premium or discount relative to its financial performance.

Collegium's revenue for Q2 2026 was $199.9 million, a 6.3% increase year-over-year but below analyst expectations. The adjusted EPS was $1.92, exceeding estimates, indicating some operational strength despite revenue challenges. However, the net income for Q2 was negative at -$15.05 million, reflecting significant financial strain.